Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33361655

about

Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study.Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma Advances in non-surgical management of primary liver cancer.A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.Systemic treatment of hepatocellular carcinoma: Past, present and future 0404 inhibits hepatocellular carcinoma through a p53/miR-34a/SIRT1 positive feedback loop Cisplatin-Based Combination Chemotherapy for Advanced Hepatocellular Carcinoma: A Single Center Experience before the Sorafenib Era.Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases.Targeted therapy in hepatocellular carcinoma Early development of sunitinib in hepatocellular carcinoma.Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy.Antiproliferation and apoptosis induction of paeonol in HepG2 cells.An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.Evolution of systemic therapy of advanced hepatocellular carcinoma.MicroRNA-200a/b influenced the therapeutic effects of curcumin in hepatocellular carcinoma (HCC) cells.Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma.

P2860

Q25257445-63B7E15E-7732-454A-BB14-FBD80E3E75AA Q26851627-5D515BB2-ABB3-4A8C-BF97-5C5FC4125679 Q28392783-675D2F13-409B-41C2-AD21-9AC081821FD3 Q28394414-CCF82745-9BE3-419A-8251-B9A88D28F74C Q30423781-BBA4A505-39B0-49BB-A5BE-8970F5914600 Q33368982-1388B0CC-04C3-4BF2-95AB-B3D5E7438B30 Q33415172-12F95050-B61C-487E-A7A0-05EB02655EFC Q33635033-81CE1FC3-BBC9-4567-A321-5D0A8AA54BAF Q33854034-736F7314-DE3A-4D48-BB9C-AD454FCAA4BF Q33861041-295CF877-5E8C-46F6-AE8A-1209CC53F221 Q34494749-B649DBC5-719C-4DA6-8BE2-99EFE7259B68 Q34563336-ABEB7E8D-9D9D-4036-8307-56751B430DD2 Q35207561-588903D6-5FA2-43C9-9ACA-CAD745F70616 Q37357314-C251EE63-002F-42D2-9FC5-1DABA449E86F Q39289689-38A3EB44-9329-4526-B047-437C4E5B9C15 Q40182721-2711F65B-1D5A-40B5-9137-3CEC4873D72A Q40706069-F9B84BE7-2003-4CDC-91DB-785EC2FC0A53 Q42343451-548D3B1F-53A0-40CB-B43C-FDD6559D9731 Q42617015-E4A2E8AE-8D05-41E2-B16D-2C29476A195C Q44233033-382480C8-66BA-405A-8A45-DBB47979864F Q47869247-6E6F6771-CCFD-4884-9959-6E26F0837BF7

P2860

Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33361655

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phase II study of doxorubicin ...... atic hepatocellular carcinoma.

@ast

Phase II study of doxorubicin ...... atic hepatocellular carcinoma.

@en

type

label

Phase II study of doxorubicin ...... atic hepatocellular carcinoma.

@ast

Phase II study of doxorubicin ...... atic hepatocellular carcinoma.

@en

prefLabel

Phase II study of doxorubicin ...... atic hepatocellular carcinoma.

@ast

Phase II study of doxorubicin ...... atic hepatocellular carcinoma.

@en

P1433

Q33361655-54161B1E-5120-4CC4-8208-DF931D48D180

P1476

Q33361655-DF8F0C7B-3A4B-4281-AA3F-ED6504D344AD

P2093

Q33361655-0BACA51D-BB44-46FA-9B3B-74F1B7AAD85F

Q33361655-0DC130A7-DEDE-4212-9DF0-9E3E58BD9D56

Q33361655-0DE2B13F-5FFA-45CB-AA33-A8E9285A51F2

Q33361655-0E5C6813-3B4D-4E15-B362-46DF3BDF185B

Q33361655-1F8A37DD-4B5F-4F1D-BEEA-EF52B0BF64AC

Q33361655-435BA134-76A6-412D-A6DC-2BB89087083D

Q33361655-4F209DA6-8325-4607-B47A-FCD0BAF86D44

Q33361655-4F4DDF71-056B-463E-A210-8DE7CA4A38F9

Q33361655-5CF09BAE-B9E1-4B08-93A6-DE2B24C36CA6

Q33361655-5EA4991A-748F-471C-BF23-01006A50089D

P2888

Q33361655-7B2DFEEB-C8C4-4D35-90A3-959A9B1F30EF

P304

Q33361655-3DE81EF9-F210-41F6-B45C-A981786AC76C

P31

Q33361655-6951B5BD-309F-43A3-8773-DB16A24A7CEB

P356

Q33361655-8B138BCD-95E9-43C1-83B4-251213AFE1EE

P433

Q33361655-16701F7B-A026-498B-9F8D-E2E86B41E576

P478

Q33361655-070692A1-3784-4E1A-BF36-C436F6677FF0

P50

Q33361655-B1AC6AEB-248B-42F2-ACD1-E5C5325184CA

P577

Q33361655-A2015C11-E2BF-4E8D-B883-311308645E12

P6179

Q33361655-395695CE-5476-47F6-9B25-5621E8950D26

P698

Q33361655-619ED2CA-E284-4508-812B-33929A03F7ED

P356

S00280-004-0837-7

P1433

Cancer Chemotherapy and Pharmacology

P1476

Phase II study of doxorubicin ...... atic hepatocellular carcinoma.

@en

P2093

Byung Chul Yoo

http://www.w3.org/2001/XMLSchema#string

Chul Won Jung

http://www.w3.org/2001/XMLSchema#string

Jaewon Joh

http://www.w3.org/2001/XMLSchema#string

Jeeyun Lee

http://www.w3.org/2001/XMLSchema#string

Joon Hyoek Lee

http://www.w3.org/2001/XMLSchema#string

Joon Oh Park

http://www.w3.org/2001/XMLSchema#string

Keon Woo Park

http://www.w3.org/2001/XMLSchema#string

Keunchil Park

http://www.w3.org/2001/XMLSchema#string

Kwang Cheol Koh

http://www.w3.org/2001/XMLSchema#string

Mark H Lee

http://www.w3.org/2001/XMLSchema#string

P2888

s00280-004-0837-7

P304

385-390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-004-0837-7

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-07-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047246165

http://www.w3.org/2001/XMLSchema#string

P698

15248028

http://www.w3.org/2001/XMLSchema#string